Data from the phase 1/2 LIBRETTO-001 trial support the FDA approval of selpercatinib in patients with RET fusion-positive thyroid cancer.
Approval Alert | Selpercatinib in RET+ Thyroid Cancer
Data from the phase 1/2 LIBRETTO-121 trial led to the approval of selpercatinib in pediatric RET-mutant thyroid cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Iberdomide Combo in Relapsed/Refractory Multiple Myeloma
2
Iza-Bren Yields Encouraging Activity in Extensive-Stage SCLC
3
How AI and Health Networks Are Democratizing Clinical Trial Access
4
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20 NSCLC
5